{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:40:46Z","timestamp":1761864046740,"version":"build-2065373602"},"reference-count":40,"publisher":"Elsevier BV","issue":"23","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T00:00:00Z","timestamp":1607472000000},"content-version":"vor","delay-in-days":374,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Cardiovascular Interventions"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.jcin.2019.08.039","type":"journal-article","created":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T16:00:37Z","timestamp":1575302437000},"page":"2331-2341","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation"],"prefix":"10.1016","volume":"12","author":[{"given":"Jurrien M.","family":"ten Berg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"de Veer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonas","family":"Oldgren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe Gabriel","family":"Steg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dmitry A.","family":"Zateyshchikov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petr","family":"Jansky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ki-Bae","family":"Seung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan H.","family":"Hohnloser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory Y.H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matias","family":"Nordaby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Kleine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher P.","family":"Cannon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcin.2019.08.039_bib1","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1160\/TH10-05-0332","article-title":"Atherothrombosis and atrial fibrillation: important and often overlapping clinical syndromes","volume":"104","author":"Depta","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jcin.2019.08.039_bib2","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.amjcard.2009.06.027","article-title":"Patient characteristics associated with the choice of triple antithrombotic therapy in acute coronary syndromes","volume":"104","author":"Depta","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jcin.2019.08.039_bib3","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.ahj.2008.06.029","article-title":"Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis","volume":"156","author":"Goto","year":"2008","journal-title":"Am Heart J"},{"key":"10.1016\/j.jcin.2019.08.039_bib4","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.jacc.2015.05.062","article-title":"Use and outcomes of triple therapy among older patients with acute myocardial infarction and atrial fibrillation","volume":"66","author":"Hess","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2019.08.039_bib5","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ijcard.2013.11.030","article-title":"Long-term cardiovascular outcomes in patients with atrial fibrillation and atherothrombosis in the REACH Registry","volume":"170","author":"Ruff","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jcin.2019.08.039_bib6","first-page":"93","article-title":"Viewpoint: a proposal for a simple algorithm for managing oral anticoagulation and antiplatelet therapy in patients with non-valvular atrial fibrillation and coronary stents","volume":"6","author":"Steg","year":"2017","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"10.1016\/j.jcin.2019.08.039_bib7","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1093\/eurheartj\/ehu278","volume":"35","author":"Windecker","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2019.08.039_bib8","first-page":"1455","article-title":"Management of antithrombotic therapy after bleeding in patients with coronary artery disease and\/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis","volume":"38","author":"Halvorsen","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2019.08.039_bib9","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2019.08.039_bib10","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","volume":"37","author":"Roffi","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2019.08.039_bib11","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2019.08.039_bib12","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1161\/CIRCULATIONAHA.118.034722","article-title":"Antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a North American perspective\u20142018 update","volume":"138","author":"Angiolillo","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2019.08.039_bib13","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/archinternmed.2010.271","article-title":"Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation","volume":"170","author":"Hansen","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jcin.2019.08.039_bib14","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.jacc.2007.02.027","article-title":"Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY trial","volume":"49","author":"Manoukian","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2019.08.039_bib15","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jcin.2019.08.039_bib16","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehy162","article-title":"Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials","volume":"39","author":"Golwala","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2019.08.039_bib17","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1160\/TH16-11-0876","article-title":"Stroke prevention in atrial fibrillation: Past, present and future. Comparing the guidelines and practical decision-making","volume":"117","author":"Lip","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jcin.2019.08.039_bib18","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2019.08.039_bib19","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1160\/TH17-08-0555","article-title":"Regional differences in antithrombotic treatment for atrial fibrillation: insights from the GLORIA-AF Phase II Registry","volume":"117","author":"Mazurek","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jcin.2019.08.039_bib20","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2019.08.039_bib21","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2019.08.039_bib22","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2019.08.039_bib23","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2019.08.039_bib24","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2019.08.039_bib25","doi-asserted-by":"crossref","first-page":"381","DOI":"10.4244\/EIJY14M06_07","article-title":"Uninterrupted oral anticoagulation versus bridging in patients with long-term oral anticoagulation during percutaneous coronary intervention: subgroup analysis from the WOEST trial","volume":"11","author":"Dewilde","year":"2015","journal-title":"EuroIntervention"},{"key":"10.1016\/j.jcin.2019.08.039_bib26","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ahj.2014.09.006","article-title":"Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial","volume":"169","author":"Granger","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.jcin.2019.08.039_bib27","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1253\/circj.CJ-11-1206","article-title":"Heparin bridging vs. uninterrupted oral anticoagulation in patients with atrial fibrillation undergoing coronary artery stenting. Results from the AFCAS registry","volume":"76","author":"Lahtela","year":"2012","journal-title":"Circ J"},{"key":"10.1016\/j.jcin.2019.08.039_bib28","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1161\/CIRCOUTCOMES.113.000132","article-title":"End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience","volume":"6","author":"Mahaffey","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jcin.2019.08.039_bib29","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.jacc.2012.09.057","volume":"61","author":"Patel","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2019.08.039_bib30","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.jacc.2014.05.028","article-title":"Transition of patients from blinded study drug to open-label anticoagulation: the ENGAGE AF-TIMI 48 trial","volume":"64","author":"Ruff","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2019.08.039_bib31","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/clc.22572","volume":"39","author":"Cannon","year":"2016","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jcin.2019.08.039_bib32","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.1016\/S2352-3026(15)00027-7","article-title":"Risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort study","volume":"2","author":"Bouillon","year":"2015","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jcin.2019.08.039_bib33","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.amjmed.2014.01.031","article-title":"Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation","volume":"127","author":"Larsen","year":"2014","journal-title":"Am J Med"},{"key":"10.1016\/j.jcin.2019.08.039_bib34","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-002758","article-title":"Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study","volume":"3","author":"S\u00f8rensen","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.jcin.2019.08.039_bib35","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1161\/CIRCULATIONAHA.110.973735","article-title":"Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation","volume":"122","author":"Ezekowitz","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2019.08.039_bib36","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.ahj.2013.05.016","article-title":"Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial","volume":"166","author":"Garcia","year":"2013","journal-title":"Am Heart J"},{"key":"10.1016\/j.jcin.2019.08.039_bib37","doi-asserted-by":"crossref","first-page":"861","DOI":"10.7326\/0003-4819-158-12-201306180-00003","article-title":"Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial","volume":"158","author":"Mahaffey","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jcin.2019.08.039_bib38","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ijcard.2014.09.099","article-title":"Thromboembolic risk in the initiation, switch and interruption\/re-initiation of oral anticoagulants: do\u00a0newcomers improve outcomes? Insights from a\u00a0meta-analysis of RCTs","volume":"177","author":"Caldeira","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jcin.2019.08.039_bib39","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1161\/CIRCULATIONAHA.111.090464","article-title":"Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial","volume":"126","author":"Healey","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2019.08.039_bib40","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1161\/CIRCULATIONAHA.113.005754","volume":"129","author":"Sherwood","year":"2014","journal-title":"Circulation"}],"container-title":["JACC: Cardiovascular Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936879819318552?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936879819318552?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T18:10:39Z","timestamp":1761847839000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936879819318552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":40,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S1936879819318552"],"URL":"https:\/\/doi.org\/10.1016\/j.jcin.2019.08.039","relation":{},"ISSN":["1936-8798"],"issn-type":[{"type":"print","value":"1936-8798"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation","name":"articletitle","label":"Article Title"},{"value":"JACC: Cardiovascular Interventions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcin.2019.08.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}